Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 1, 2025Neuro-OncologyOpen Access

DDDR-73. Preclinical evaluation of blood brain permeable, novel nicotinamide phosphoribosyl-transferase (NAMPT) inhibitor in gliomas

View Full Paper
Ask AI
Bookmark
Share

Authors

PSPratibha SharmaLHLongfei HuoHSHarsha Sugur

Discussion

Loading...

Member takes

Overview

Preclinical findings reveal gliomas depend on NAMPT, implying novel inhibitors can enhance therapeutic strategies.

Key Points

  • This study evaluates the efficacy of NAMPT inhibitors in targeting gliomas' reliance on NAD synthesis.
  • Tested NAMPT inhibitors in glioma stem-like cells and normal cells to assess viability and toxicity.
  • Measured cell cycle changes through flow cytometry and programmed cell death quantification.
  • Conducted in vivo assessments in athymic nude mice using intracranial glioma models.
  • NAMPT inhibitors reduced proliferation in diverse glioma cell lines without harming normal cells.
  • RPT-E-50 demonstrated superior efficacy, enhancing programmed cell death and survival advantage in mouse models.

Cite This Study

Sharma et al. (2025) studied this question.

synapsesocial.com/papers/69254362c0ce034ddc3582b5https://doi.org/10.1093/neuonc/noaf201.0710
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Exploiting Metabolic Defects in Glioma with Nanoparticle-Encapsulated NAMPT Inhibitors2024 · 6 citations
  2. 2Abstract 419: Targeting NAMPT using Novel Inhibitor RPT-E-037 in Pancreatic Neuroendocrine Tumor.2026
  3. 3First-in-human randomized placebo-controlled Phase 1 study of RPT1G, a novel hyperbolic NAMPT inhibitor for use in acute leukemias: Safety, pharmacokinetics, and pharmacodynamics in healthy volunteers2025 · 2 citations
  4. 4Data from Exploiting Metabolic Defects in Glioma with Nanoparticle-Encapsulated NAMPT Inhibitors2024
  5. 5Abstract 4568: Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) impairs cellular viability, affects energy metabolism, induces DNA damage, and drives tumor regression in preclinical models of neuroblastoma2026